Publications

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.  2018.  The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^.. Leuk Lymphoma. 59(1):256-258.

Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MNieves et al..  2018.  Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.. Blood. 132(19):2016-2025.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.  2017.  The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.. Leuk Lymphoma. :1-3.